FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313304103> ?p ?o ?g. }

• W4313304103 endingPage "614" @default.
• W4313304103 startingPage "606" @default.
• W4313304103 abstract "This retrospective, multicenter study evaluated the effect of pemafibrate treatment on liver function and fibrosis by liver function tests (LFTs) and various fibrotic biomarkers including FibroScan in non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia.A total of 138 NAFLD patients treated with pemafibrate at three hospitals between September 2018 and April 2021 were included. To evaluate the effect of pemafibrate treatment, FibroScan-aspartate aminotransferase (FAST) score, a novel index of steatohepatitis that can be calculated based on the aspartate aminotransferase (AST) value, controlled attenuation parameter (CAP), and liver stiffness measurement (LSM) was used.Serum TG levels were significantly decreased 4 weeks after pemafibrate treatment (p = 0.003). The levels of AST (p = 0.038), alanine aminotransferase (ALT) (p = 0.003), and gamma-glutamyl transferase (GGT) (p = 0.047) also significantly diminished 12 weeks after pemafibrate administration compared to before administration (p < 0.05). However, serum HDL-cholesterol (p = 0.193), LDL-cholesterol (p = 0.967), and eGFR (p = 0.909) levels were not significantly altered 12 weeks after pemafibrate administration. In addition, the fibrosis biomarkers' Type IV collagen (p = 0.753) and FIB-4 index (p = 0.333) did not significantly differ, while Autotaxin (p = 0.006) and the AST-to-platelet ratio index (APRI) (p = 0.003) significantly decreased 48 weeks after pemafibrate administration. No significant reductions in LSM (p = 0.959) and CAP (p = 0.266) were detected using FibroScan 48 weeks after pemafibrate administration. FAST score was significantly improved (p = 0.0475).Pemafibrate improved LFTs, including fibrotic biomarkers and FAST score, due to the hepatic anti-inflammatory effect, suggesting that pemafibrate may prevent disease progression in NAFLD patients with hypertriglyceridemia." @default.
• W4313304103 created "2023-01-06" @default.
• W4313304103 creator A5003480697 @default.
• W4313304103 creator A5010387793 @default.
• W4313304103 creator A5013902375 @default.
• W4313304103 creator A5017931660 @default.
• W4313304103 creator A5028991887 @default.
• W4313304103 creator A5032563585 @default.
• W4313304103 creator A5046725215 @default.
• W4313304103 creator A5047492780 @default.
• W4313304103 creator A5050706722 @default.
• W4313304103 creator A5059940557 @default.
• W4313304103 creator A5067453067 @default.
• W4313304103 creator A5069413957 @default.
• W4313304103 creator A5072760293 @default.
• W4313304103 creator A5075621924 @default.
• W4313304103 creator A5085574358 @default.
• W4313304103 creator A5085777607 @default.
• W4313304103 creator A5088307695 @default.
• W4313304103 date "2022-12-30" @default.
• W4313304103 modified "2023-10-13" @default.
• W4313304103 title "Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study" @default.
• W4313304103 cites W1549627000 @default.
• W4313304103 cites W1606178710 @default.
• W4313304103 cites W1997865776 @default.
• W4313304103 cites W2000142355 @default.
• W4313304103 cites W2005046746 @default.
• W4313304103 cites W2027293462 @default.
• W4313304103 cites W2029724392 @default.
• W4313304103 cites W2035962070 @default.
• W4313304103 cites W2038654926 @default.
• W4313304103 cites W2039117042 @default.
• W4313304103 cites W2065612971 @default.
• W4313304103 cites W2072362233 @default.
• W4313304103 cites W2081324449 @default.
• W4313304103 cites W2088337379 @default.
• W4313304103 cites W2096546399 @default.
• W4313304103 cites W2098207315 @default.
• W4313304103 cites W2112316124 @default.
• W4313304103 cites W2112496618 @default.
• W4313304103 cites W2113328569 @default.
• W4313304103 cites W2118655749 @default.
• W4313304103 cites W2132783496 @default.
• W4313304103 cites W2156696514 @default.
• W4313304103 cites W2534155301 @default.
• W4313304103 cites W2578670173 @default.
• W4313304103 cites W2588037944 @default.
• W4313304103 cites W2613759826 @default.
• W4313304103 cites W2618863496 @default.
• W4313304103 cites W2734724639 @default.
• W4313304103 cites W2754192704 @default.
• W4313304103 cites W2793937758 @default.
• W4313304103 cites W2909142264 @default.
• W4313304103 cites W2914961474 @default.
• W4313304103 cites W2929809507 @default.
• W4313304103 cites W2971075453 @default.
• W4313304103 cites W2980992948 @default.
• W4313304103 cites W2981574224 @default.
• W4313304103 cites W2989927463 @default.
• W4313304103 cites W3004950447 @default.
• W4313304103 cites W3022627642 @default.
• W4313304103 cites W3047965158 @default.
• W4313304103 cites W3087664331 @default.
• W4313304103 cites W3092644965 @default.
• W4313304103 cites W3131743383 @default.
• W4313304103 cites W3143409077 @default.
• W4313304103 cites W3198111024 @default.
• W4313304103 cites W3201123873 @default.
• W4313304103 cites W3208173424 @default.
• W4313304103 cites W4200167497 @default.
• W4313304103 cites W4223971742 @default.
• W4313304103 cites W4294598083 @default.
• W4313304103 doi "https://doi.org/10.1007/s12072-022-10453-1" @default.
• W4313304103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36583842" @default.
• W4313304103 hasPublicationYear "2022" @default.
• W4313304103 type Work @default.
• W4313304103 citedByCount "4" @default.
• W4313304103 countsByYear W43133041032023 @default.
• W4313304103 crossrefType "journal-article" @default.
• W4313304103 hasAuthorship W4313304103A5003480697 @default.
• W4313304103 hasAuthorship W4313304103A5010387793 @default.
• W4313304103 hasAuthorship W4313304103A5013902375 @default.
• W4313304103 hasAuthorship W4313304103A5017931660 @default.
• W4313304103 hasAuthorship W4313304103A5028991887 @default.
• W4313304103 hasAuthorship W4313304103A5032563585 @default.
• W4313304103 hasAuthorship W4313304103A5046725215 @default.
• W4313304103 hasAuthorship W4313304103A5047492780 @default.
• W4313304103 hasAuthorship W4313304103A5050706722 @default.
• W4313304103 hasAuthorship W4313304103A5059940557 @default.
• W4313304103 hasAuthorship W4313304103A5067453067 @default.
• W4313304103 hasAuthorship W4313304103A5069413957 @default.
• W4313304103 hasAuthorship W4313304103A5072760293 @default.
• W4313304103 hasAuthorship W4313304103A5075621924 @default.
• W4313304103 hasAuthorship W4313304103A5085574358 @default.
• W4313304103 hasAuthorship W4313304103A5085777607 @default.
• W4313304103 hasAuthorship W4313304103A5088307695 @default.
• W4313304103 hasBestOaLocation W43133041031 @default.
• W4313304103 hasConcept C126322002 @default.

• next